Today: 19 May 2026
Browse Category

NYSE:KMB 22 November 2025 - 23 January 2026

Kenvue stock ticks up as investors size up Kimberly-Clark takeover vote in days

Kenvue stock ticks up as investors size up Kimberly-Clark takeover vote in days

Kenvue shares rose 0.6% to $17.31 in late-morning New York trading Tuesday as investors awaited a Jan. 29 shareholder vote on its proposed sale to Kimberly-Clark. The deal’s outcome remains uncertain amid ongoing litigation risks tied to Kenvue’s legacy products. ISS has backed the merger but flagged legal concerns. Kenvue’s virtual shareholder meeting is scheduled for 9:00 a.m. Eastern on Jan. 29.
20 January 2026
··
Johnson & Johnson stock heads into earnings after a mild dip — what could move JNJ next

Johnson & Johnson stock heads into earnings after a mild dip — what could move JNJ next

Johnson & Johnson shares closed down 0.4% at $218.66 Friday ahead of the Martin Luther King Jr. Day market holiday. The S&P 500 health care sector fell 0.8%. J&J reports fourth-quarter results Wednesday, Jan. 21, with investors focused on earnings and 2026 guidance. The NYSE will reopen Tuesday after the holiday.
18 January 2026
·······
Kenvue stock has a new catalyst: ISS backs Kimberly-Clark merger ahead of Jan. 29 vote

Kenvue stock has a new catalyst: ISS backs Kimberly-Clark merger ahead of Jan. 29 vote

Kenvue shares closed at $17.20 Friday, down 0.35%, ahead of a Jan. 29 shareholder vote on its sale to Kimberly-Clark. Proxy adviser ISS recommended investors back the deal but cited ongoing legal and market risks. Kenvue updated merger disclosures after lawsuits challenged the process. The offer values Kenvue at about $18.03 per share, a 4.6% premium to Friday’s close.
18 January 2026
··
Kenvue stock edges up as Kimberly-Clark vote nears — the deal spread traders are watching

Kenvue stock edges up as Kimberly-Clark vote nears — the deal spread traders are watching

Kenvue shares rose 0.4% to $17.08 in mid-morning trading after Kimberly-Clark filed new deal documents with U.S. regulators. The stock remains about 5% below the value implied by the pending cash-and-stock takeover. Kenvue shareholders are set to vote on the deal Jan. 29. The transaction’s value fluctuates with Kimberly-Clark’s share price.
14 January 2026
···
Kenvue (KVUE) stock nudges up as fresh deal scrutiny hits — and the spread traders are watching

Kenvue (KVUE) stock nudges up as fresh deal scrutiny hits — and the spread traders are watching

Kenvue shares rose 0.8% to $16.87 Thursday after law firm Kahn Swick & Foti said it is investigating the company’s pending sale to Kimberly-Clark. The offer values Kenvue at about $17.91 per share, a 6% premium to Thursday’s price. Shareholders are set to vote on the deal in late January. Kenvue also named Madhav Nayak as vice president and chief marketing officer for Asia-Pacific.
8 January 2026
··
Kenvue Stock (NYSE: KVUE) News Today: Kimberly-Clark Deal Update, Insider Buying, Analyst Forecasts — December 25, 2025

Kenvue Stock (NYSE: KVUE) News Today: Kimberly-Clark Deal Update, Insider Buying, Analyst Forecasts — December 25, 2025

Kenvue shares closed December 24 at $17.21, up 1.12% in light holiday trading, as investors weigh Kimberly-Clark’s pending acquisition. The agreed deal values KVUE at about $18.28 per share based on current KMB prices, but the stock trades below that level amid regulatory, timing, and legal uncertainties. The transaction is expected to close in the second half of 2026.
25 December 2025
··
Kenvue Stock (KVUE) News, Forecasts and Analysis for December 23, 2025: Deal Math, Legal Headlines, and What Investors Are Watching

Kenvue Stock (KVUE) News, Forecasts and Analysis for December 23, 2025: Deal Math, Legal Headlines, and What Investors Are Watching

A Baltimore jury ordered Johnson & Johnson and spinoff Kenvue to pay over $1.5 billion in a talc cancer case, with J&J saying it will appeal. Kenvue shares traded at $16.98, about $1.15 below the implied $18.12 merger value based on Kimberly-Clark’s price, reflecting deal risk. The acquisition is expected to close in the second half of 2026. J&J has said it will cover Kenvue’s talc liabilities.
23 December 2025
···
Kenvue Stock (KVUE) News Today: Deal Spread Math, Kimberly-Clark Vote Timeline, Tylenol Lawsuits, and Analyst Forecasts (Dec. 19, 2025)

Kenvue Stock (KVUE) News Today: Deal Spread Math, Kimberly-Clark Vote Timeline, Tylenol Lawsuits, and Analyst Forecasts (Dec. 19, 2025)

Kenvue shares closed at $17.10 on Dec. 19, 2025, down 1.04% amid heavy trading. Kimberly-Clark’s pending cash-and-stock acquisition values Kenvue at about $18.35 per share, based on current prices, leaving a deal spread of roughly 7%. The merger awaits shareholder and regulatory approval, with legal risks and earnings pressure influencing the stock.
19 December 2025
··
Kenvue Stock (KVUE) Today: Latest News, Deal Outlook, Analyst Forecasts and Key Risks (Dec. 15, 2025)

Kenvue Stock (KVUE) Today: Latest News, Deal Outlook, Analyst Forecasts and Key Risks (Dec. 15, 2025)

Kenvue shares traded near $17.33 midday Monday, about 7% below the implied $18.59 value of Kimberly-Clark’s pending cash-and-stock offer. The gap reflects market uncertainty as the $48.7 billion deal awaits regulatory and shareholder approval, with closing expected in the second half of 2026. Kimberly-Clark shares stood at $103.15. New legal filings and shareholder law firm activity surfaced Monday.
15 December 2025
··
KVUE Stock Today (Nov. 22, 2025): Kenvue Rises as Kimberly‑Clark Deal, Dividend and Tylenol Ruling Shape Outlook

KVUE Stock Today (Nov. 22, 2025): Kenvue Rises as Kimberly‑Clark Deal, Dividend and Tylenol Ruling Shape Outlook

Kenvue shares closed at $16.64 in late Friday trading, up 3% on heavy volume, but still about 12% below the value implied by Kimberly-Clark’s takeover offer. The deal, announced November 3 and valued at $48–49 billion, would pay Kenvue holders $3.50 in cash plus 0.14625 KMB shares per KVUE share. Both boards approved the merger, expected to close in the second half of 2026.
22 November 2025
·
1 2 3

Stock Market Today

  • LeMaitre Q1 Performance Trails Surgical Equipment Sector Leaders
    May 19, 2026, 5:33 AM EDT. LeMaitre (NASDAQ:LMAT) reported Q1 revenue of $66.55 million, up 11.2% year-on-year but missed the mark relative to analyst estimates and offered weaker full-year guidance than peers. Despite beating earnings per share (EPS) estimates for the upcoming quarter, LMAT's stock fell 10%, trading at $100.83. In contrast, sector leader Intuitive Surgical (NASDAQ:ISRG) delivered a 23% revenue increase to $2.77 billion, surpassing expectations by 5.8%, driven by its robotic-assisted surgical systems business. The surgical equipment and consumables sector as a whole beat revenue estimates by 2.7% for Q1, with stocks rising an average of 6.4%. Industry growth is underpinned by aging populations and expanding use of AI and robotics, although challenges remain around R&D costs, regulatory compliance, pricing pressures, and potential supply chain issues.

Latest articles

Alphabet Approaches $5 Trillion With Google AI Cloud Move Targeting Nvidia

Alphabet Approaches $5 Trillion With Google AI Cloud Move Targeting Nvidia

19 May 2026
Alphabet shares rose in pre-market trading Tuesday after Google and Blackstone announced a U.S. AI cloud venture, with Blackstone committing $5 billion to add 500 megawatts of data-center capacity by 2027. Alphabet’s Class A shares closed Monday at $396.94 and were quoted at $401.09 before the market opened. The move coincides with the first day of Google I/O and follows strong Q1 earnings.
GeoVax Stock Rockets Nearly 80% as Tiny Vaccine Developer Grabs Biodefense Spotlight

GeoVax Stock Rockets Nearly 80% as Tiny Vaccine Developer Grabs Biodefense Spotlight

19 May 2026
GeoVax Labs shares surged nearly 80% to $2.21 Monday after announcing a $3 million private placement amid heightened interest in biodefense following a WHO emergency alert over Ebola in Africa. The company does not sell an approved Ebola vaccine; its lead candidate targets mpox and smallpox. GeoVax reported $1.3 million in cash at March 31 and a quarterly net loss of $5.3 million. The new funding is expected to close around May 19.
Evolution stock jumps on €2 billion move

Evolution stock jumps on €2 billion move

19 May 2026
Evolution AB shares surged 9% in Stockholm after the company announced a €2 billion share buyback, one of Sweden’s largest. The buyback starts immediately and may run until the 2027 annual meeting, capped at 10% of shares. The OMXS30 index rose just 0.75% in comparison. Evolution also secured a €300 million revolving credit facility from J.P. Morgan SE and Citibank Europe.

Popular

Sunshine Biopharma Shares Volatile After $6M Deal, 50-Cent Mark in Focus

Sunshine Biopharma Shares Volatile After $6M Deal, 50-Cent Mark in Focus

19 May 2026
Sunshine Biopharma shares surged as much as 516% before settling up 78% at $0.51 in heavy after-hours Nasdaq trading Monday, following a $6 million public offering priced at $0.50 per unit. More than 436 million shares changed hands, far exceeding the company’s 5 million shares outstanding. The deal includes 12 million units with warrants, raising dilution concerns. Closing is expected around May 19.
Go toTop